162 related articles for article (PubMed ID: 3556193)
1. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
[TBL] [Abstract][Full Text] [Related]
3. Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily.
Olowoyeye JO; Thadani U; Parker JO
Am J Cardiol; 1981 May; 47(5):1123-7. PubMed ID: 7223659
[TBL] [Abstract][Full Text] [Related]
4. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
[TBL] [Abstract][Full Text] [Related]
5. Slow release oxprenolol in angina pectoris [proceedings].
Goldstraw PW; Taylor SH; Thadani U; Watt SJ
Br J Clin Pharmacol; 1977 Jun; 4(3):387P. PubMed ID: 332219
[No Abstract] [Full Text] [Related]
6. A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study.
Floris B; Paoletti G; Pelizza L; Bertulla A; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):139-43. PubMed ID: 1906434
[TBL] [Abstract][Full Text] [Related]
7. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina.
Klein WW; Khurmi NS; Eber B; Dusleag J
J Am Coll Cardiol; 1990 Oct; 16(4):948-56. PubMed ID: 2212376
[TBL] [Abstract][Full Text] [Related]
8. Ambulatory monitoring and exercise testing in the evaluation of a new long-acting calcium ion antagonist KB-944 (Fostedil) for the treatment of exertional angina pectoris.
Khurmi NS; Bowles MJ; O'Hara MJ; Lahiri A; Raftery EB
Int J Cardiol; 1985 Nov; 9(3):289-302. PubMed ID: 3902675
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
McInnes GT; Brodie MJ
Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of once daily penbutolol in chronic stable angina. An objective comparison with long-acting propranolol.
Bowles MJ; Khurmi NS; Bala Subramanian V; Raftery EB
Int J Cardiol; 1984 Feb; 5(2):131-42. PubMed ID: 6365803
[TBL] [Abstract][Full Text] [Related]
11. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group.
Frishman WH; Pepine CJ; Weiss RJ; Baiker WM
J Am Coll Cardiol; 1995 Aug; 26(2):305-12. PubMed ID: 7608428
[TBL] [Abstract][Full Text] [Related]
12. Experience with a sustained-release formulation of oxprenolol in the management of angina pectoris in hospital out-patient departments.
Forrest WA
Curr Med Res Opin; 1978; 5(9):669-74. PubMed ID: 104825
[TBL] [Abstract][Full Text] [Related]
13. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sustained-release diltiazem in stable angina pectoris.
Weiner DA; Cutler SS; Klein MD
Am J Cardiol; 1986 Jan; 57(1):6-9. PubMed ID: 3510525
[TBL] [Abstract][Full Text] [Related]
15. Are anti-platelet drugs of value in the management of patients with chronic stable angina? A study with ticlopidine.
Khurmi NS; Bowles MJ; Raftery EB
Clin Cardiol; 1986 Oct; 9(10):493-8. PubMed ID: 3533337
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.
Thadani U; Davidson C; Singleton W; Taylor SH
N Engl J Med; 1979 Apr; 300(14):750-5. PubMed ID: 581782
[TBL] [Abstract][Full Text] [Related]
17. Treatment of angina pectoris with nifedipine: a double blind comparison of nifedipine and slow-release nifedipine alone and in combination with atenolol.
Crake T; Quyyumi AA; Wright C; Mockus L; Fox KM
Br Heart J; 1987 Dec; 58(6):617-20. PubMed ID: 3322352
[TBL] [Abstract][Full Text] [Related]
18. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
Resnekov EB; Havard CW
Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
[TBL] [Abstract][Full Text] [Related]
19. Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects on angina, exercise tolerance, and the ambulatory electrocardiographic ST segment.
Frishman W; Charlap S; Kimmel B; Teicher M; Cinnamon J; Allen L; Strom J
Circulation; 1988 Apr; 77(4):774-86. PubMed ID: 3280158
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of oxprenolol in angina pectoris.
Sandler G; Pistevos A
Br Heart J; 1972 Aug; 34(8):847-50. PubMed ID: 4560824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
